This formulation’s suitability for deep lung delivery, coupled with the maintenance of bevacizumab’s anti-VEGF bioactivity and its efficacy at lower doses than intravenous controls in a rat NSCLC model, underscores the potential of such innovative formulations [136]. Here, VEGFA is linked to non-small cell lung carcinoma.